JULIANA HAGAN: Open Payments
NPI 1215656509 · MEDIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$347 in 18 payments from 12 companies in 2025. Trend: 2023 $574 · 2024 $924 · 2025 $347
Food & beverage: $347
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Novo Nordisk Inc | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| Amgen Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
Products named: INGREZZA, VRAYLAR, REXULTI, JARDIANCE, QULIPTA, TRELEGY ELLIPTA, BREZTRI, ELIQUIS.
Industry payments across PA — which companies pay providers there.
